1. Home
  2. GME vs BEATW Comparison

GME vs BEATW Comparison

Compare GME & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GME
  • BEATW
  • Stock Information
  • Founded
  • GME 1996
  • BEATW 2015
  • Country
  • GME United States
  • BEATW United States
  • Employees
  • GME N/A
  • BEATW N/A
  • Industry
  • GME Electronics Distribution
  • BEATW Retail: Computer Software & Peripheral Equipment
  • Sector
  • GME Consumer Discretionary
  • BEATW Technology
  • Exchange
  • GME Nasdaq
  • BEATW Nasdaq
  • Market Cap
  • GME N/A
  • BEATW N/A
  • IPO Year
  • GME 2002
  • BEATW N/A
  • Fundamental
  • Price
  • GME $27.00
  • BEATW $0.58
  • Analyst Decision
  • GME Sell
  • BEATW
  • Analyst Count
  • GME 1
  • BEATW 0
  • Target Price
  • GME $10.00
  • BEATW N/A
  • AVG Volume (30 Days)
  • GME 5.8M
  • BEATW 4.7K
  • Earning Date
  • GME 03-25-2025
  • BEATW 03-14-2025
  • Dividend Yield
  • GME N/A
  • BEATW N/A
  • EPS Growth
  • GME N/A
  • BEATW N/A
  • EPS
  • GME 0.17
  • BEATW N/A
  • Revenue
  • GME $4,334,000,000.00
  • BEATW N/A
  • Revenue This Year
  • GME N/A
  • BEATW N/A
  • Revenue Next Year
  • GME N/A
  • BEATW N/A
  • P/E Ratio
  • GME $159.05
  • BEATW N/A
  • Revenue Growth
  • GME N/A
  • BEATW N/A
  • 52 Week Low
  • GME $9.95
  • BEATW $0.50
  • 52 Week High
  • GME $64.83
  • BEATW $0.62
  • Technical
  • Relative Strength Index (RSI)
  • GME 48.38
  • BEATW N/A
  • Support Level
  • GME $25.60
  • BEATW N/A
  • Resistance Level
  • GME $27.76
  • BEATW N/A
  • Average True Range (ATR)
  • GME 0.99
  • BEATW 0.00
  • MACD
  • GME 0.11
  • BEATW 0.00
  • Stochastic Oscillator
  • GME 55.63
  • BEATW 0.00

About BEATW Heartbeam Inc.

HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Share on Social Networks: